Department of Medicine, Columbia University, New York, NY, USA.
Diabetes Care. 2012 Sep;35(9):1858-63. doi: 10.2337/dc11-2215. Epub 2012 Jul 6.
To assess the association between serum adiponectin level and all-cause mortality in people with type 2 diabetes. Because of the insulin-sensitizing, anti-inflammatory, and antiatherogenic effects of adiponectin, we hypothesized that higher adiponectin level would be associated with lower all-cause mortality.
A total of 609 men and women aged 72 ± 6.3 years with type 2 diabetes and information on total and high molecular weight adiponectin were followed for a median of 5 years. The longitudinal association between adiponectin and all-cause mortality was analyzed with Cox proportional hazards models with time from adiponectin measurement to death as the time-to-event variable. Analyses were adjusted for demographic variables and significant diabetes parameters, significant cardiovascular parameters, and significant diabetes medications.
Total and high molecular weight adiponectin were highly correlated. The highest adiponectin quartile was strongly associated with higher all-cause mortality compared with the lowest quartile (hazard ratio = 4.0 [95% CI: 1.7-9.2]) in the fully adjusted model. These results did not change in analyses stratified by sex and thiazolidinedione use, after exclusion of people who died within one year of adiponectin measurement, or when change in weight before adiponectin measurement was considered.
Contrary to our hypothesis, higher adiponectin level was related to higher all-cause mortality. This association was not explained by confounding by other characteristics, including medications or preceding weight loss.
评估血清脂联素水平与 2 型糖尿病患者全因死亡率之间的关系。由于脂联素具有胰岛素增敏、抗炎和抗动脉粥样硬化作用,我们假设较高的脂联素水平与较低的全因死亡率相关。
共纳入 609 名年龄为 72±6.3 岁的 2 型糖尿病男性和女性,他们具有脂联素和高分子量脂联素的相关信息,并随访了中位数为 5 年。使用 Cox 比例风险模型分析脂联素与全因死亡率之间的纵向关联,时间从脂联素测量到死亡作为时间事件变量。分析调整了人口统计学变量以及重要的糖尿病参数、重要的心血管参数和重要的糖尿病药物。
总脂联素和高分子量脂联素高度相关。在完全调整模型中,最高脂联素四分位与最低四分位相比,全因死亡率明显升高(危险比=4.0[95%CI:1.7-9.2])。在按性别和噻唑烷二酮使用分层的分析中,在排除脂联素测量后一年内死亡的人群、或在考虑脂联素测量前体重变化时,这些结果并没有改变。
与我们的假设相反,较高的脂联素水平与较高的全因死亡率相关。这种关联不能用其他特征(包括药物或之前的体重减轻)的混杂来解释。